Bluebird prices gene therapy at 1.58 million euros over 5 years

65

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

http://feeds.reuters.com/~r/reuters/healthNews/~3/fM4sr50avHk/bluebird-prices-gene-therapy-at-1-58-million-euros-over-5-years-idUSKCN1TF1HP